Skip to main content
SpringerLink
Log in

Pharmacoeconomic Considerations in Assessing and Selecting Congestive Heart Failure Therapies

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Over the last two decades the incidence of congestive heart failure (CHF) has increased with aging of the population and in spite of the decline in age-adjusted mortality rates due to coronary heart disease. Its management has seen substantial progress, embodied in the introduction of ACE inhibitors, initially as part of triple therapy in which they complemented diuretics and digoxin, and latterly as first-line therapy. The current consensus on treatment of CHF has been based on the multiple clinical studies performed with ACE inhibitors in which these agents have been shown to prevent a new cardiovascular accident and/or progression to more severe CHF in an increasingly wide range of patients with symptomatic CHF or post-infarction left ventricular dysfunction (ejection fraction ≤ 40% in some trials or ≤ 35% in others). Not only have the results shown a marked decrease in all-cause (and especially cardiovascular) mortality, but also a great number of cost-effectiveness analyses have shown the advantages of ACE inhibitors in terms of resource allocation: they are either cost saving or convincingly cost effective compared with standard treatment with digoxin and diuretics.

Other drugs require similar cost and clinical analyses before they can earn their place in an add-on strategy. To date, cost savings have been documented only for β-blockers; implantable devices are still undergoing assessment. Two trends are now competing: one is to downplay add-on strategies and to recommend first-line therapy with ACE inhibitors and β-blockers at effective doses, supplemented by a raft of non-pharmaceutical measures (specialist nurses, patient education, dietary advice, exercise) in a multidisciplinary approach to CHF; the second is, on the contrary, to prescribe up to five drugs for patients with advanced CHF. The evidence that this decreases hospital admission rates and patient cost is more than anecdotal, but conclusive proof of cost effectiveness is still lacking and the approach presupposes dedicated structures.

This review argues that despite technical limitations, a combined approach of CHF therapy based on clinical trials and cost-effectiveness analyses is essential. However, improvements can be made. The absence of sufficient comparative data still makes it difficult to choose between drugs within the same class; institutional purchasers need to conduct such analyses to identify the drugs best suited to their patients’ profiles and budgetary constraints.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Delahaye F, de Gevigney G, Gaillard S, et al. Epidémiologie et impact économique de l’insuffisance cardiaque en France. Arch Mal Coeur Vaiss 1998; 91: 1307–14

    PubMed  CAS  Google Scholar 

  2. Andrews R, Cowley AJ. Clinical and economic factors in the treatment of congestive heart failure. Pharmacoeconomics 1995; 7 (2): 119–27

    Article  PubMed  CAS  Google Scholar 

  3. Launois R, Launois B, Reboul-Marty J, et al. Le coût de la sévérité de la maladie: le cas de l’insuffisance cardiaque. Journal d’Economie Médicale 1990; 8 (7–8): 395–412

    Google Scholar 

  4. McMurray JJ, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. Br J Med 1993; 6: 99–110

    Google Scholar 

  5. Davey PG, Clarkson PB, Mc Mahon A, et al. Costs associated with symptomatic systolic heart failure. Pharmacoeconomics 1999; 16 (4): 399–407

    Article  Google Scholar 

  6. Levy P, Dubois-Randé JL, Cohen-Solal A, et al. L’apport du carvedilol dans le traitement de l’insuffisance cardiaque: une étude coût-efficacité appliqué au cas de la France. Arch Mal Coeur Vaiss 2001; 94 (2): 166–70

    PubMed  CAS  Google Scholar 

  7. McMurray J, Davie A. The pharmacoeconomics of ACE inhibitors in chronic heart failure. Pharmacoeconomics 1996; 9 (3): 188–97

    Article  PubMed  CAS  Google Scholar 

  8. Levy E. From cost of illness to cost-effectiveness in heart failure. Eur Heart J 1998; 19 Suppl. P: 2–4

    Google Scholar 

  9. Kupersmith J, Holmes-Rovner M, Hogan A, et al. Cost-effectiveness analysis in heart disease, Part III: Ischemia, congestive heart failure, and arrhythmias. Prog Cardiovasc Dis 1995; 37 (5): 307–46

    Article  PubMed  CAS  Google Scholar 

  10. Galbraith A, Wright-Smith G. Heart failure. New treatment options. Aust Fam Physician 1996; 25 (7): 1035,1038–43

    Google Scholar 

  11. Parmley WW. Cost-effective management of heart failure. Clin Cardiol 1996; 19 (3): 240–2

    Article  PubMed  CAS  Google Scholar 

  12. Willens HJ, Chakko S, Simmons J, et al. Cost-effectiveness in clinical cardiology. Part 1: coronary artery disease and congestive heart failure. Chest 1996; 109 (5): 1359–69

    Article  PubMed  CAS  Google Scholar 

  13. Pepine CJ. Adjunctive therapies for acute myocardial infarction became a little clearer in 1993. J Myocardial Ischemia 1994; 6 (1): 6–7

    Google Scholar 

  14. Cleland JG. ACE inhibitors: current understanding and future directions. Br Heart J 1994; 72 (3 Suppl.): S1

    Article  PubMed  CAS  Google Scholar 

  15. Desnos M. Heart failure management: a challenge for the 3rd millennium [editorial]. Arch Mal Coeur Vaiss 1998; 91 (11): 1303

    PubMed  CAS  Google Scholar 

  16. Rich MW. Multidisciplinary interventions for the management of heart failure: where do we stand? [editorial; comment]. Am Heart J 1999; 138 (4 Pt 1): 599–601

    Article  PubMed  CAS  Google Scholar 

  17. Ward RE, Gheorghiade M, Young JB, et al. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J Am Coll Cardiol 1995; 26 (1): 93–101

    Article  PubMed  CAS  Google Scholar 

  18. Cleland JG. Health economic consequences of the pharmacological treatment of heart failure. Eur Heart J 1998; 19 Suppl. P: 32–9

    Google Scholar 

  19. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: the case of heart failure. Arch Intern Med 1999; 159 (15): 1690–700

    Article  PubMed  CAS  Google Scholar 

  20. Heaton AH, Bryant J, Berman BN, et al. A pharmacoeconomic comparison of loop diuretics in the treatment of congestive heart failure. Am J Manag Care 1996; 2: 1428–34

    Google Scholar 

  21. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341 (10): 709–17

    Article  PubMed  CAS  Google Scholar 

  22. Leizorovicz A, Cucherat M. Economic evaluation of treatments of cardiac insufficiency. Arch Mal Coeur Vaiss 1994; 87 (2): 39–44

    PubMed  Google Scholar 

  23. Young JB. Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials. Int J Cardiol 1994; 43: 151–63

    Article  PubMed  CAS  Google Scholar 

  24. Davie AP, McMurray JJ. ACE inhibitors and health-care economics. Coron Artery Dis 1995; 6 (4): 315–9

    Article  PubMed  CAS  Google Scholar 

  25. Gerbrandt KR, Yedinak KC. Formulary management of ACE inhibitors. Pharmacoeconomics 1996; 10 (6): 594–613

    Article  PubMed  CAS  Google Scholar 

  26. Giles T. The cost-effective way forward for the management of the patient with heart failure. Cardiology 1996; 87 Suppl. 1: 33–9

    Article  PubMed  Google Scholar 

  27. Szucs TD. Pharmacoeconomics of angiotensin converting enzyme inhibitors in heart failure. Am J Hypertens 1997; 10 (10 Pt 2): S272–9

    Article  Google Scholar 

  28. Boyko Jr WL, Glick HA, Schulman KA. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: ACE inhibitors in the management of congestive heart failure: comparative economic data. Am Heart J 1999; 137 (5): S115–9

    Article  PubMed  Google Scholar 

  29. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316 (23): 1429–35

    Article  Google Scholar 

  30. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314 (24): 1547–52

    Article  PubMed  CAS  Google Scholar 

  31. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325 (5): 293–302

    Article  Google Scholar 

  32. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327 (10): 685–91

    Article  Google Scholar 

  33. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327 (10): 669–77

    Article  PubMed  CAS  Google Scholar 

  34. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342 (8875): 821–8

    Google Scholar 

  35. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333 (25): 1670–6

    Article  PubMed  CAS  Google Scholar 

  36. Hart W, Rhodes G, McMurray J. The cost-effectiveness of enalapril in the treatment of chronic heart failure. Br J Med Econ 1993; 6: 91–8

    Google Scholar 

  37. van Hout BA, Wielink G, Bonsel GJ, et al. Effects of ACE inhibitors on heart failure in The Netherlands: a pharmacoeconomic model. Pharmacoeconomics 1993; 3 (5): 387–97

    Article  PubMed  Google Scholar 

  38. Paul SD, Kuntz KM, Eagle KA, et al. Cost and effectiveness of Angiotensin Converting Enzyme Inhibitor in patients with congestive heart failure. Arch Intern Med 1994; 154: 1143–9

    Article  PubMed  CAS  Google Scholar 

  39. Glick H, Cook J, Kinosian B, et al. Costs and effect of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies Of Left Ventriacular Dysfunction (SOLVD) treatment trial. J Card Fail 1995; (1): 371–80

  40. Butler JR, Fletcher PJ. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. Aust N Z J Med 1996; 26 (1): 89–95

    Article  PubMed  CAS  Google Scholar 

  41. Scott WG, Scott HM. Heart failure: a decision analytic analysis of New Zealand data using the published results of the SOLVD Treatment Trial. Studies of Left Ventricular Dysfunction. Pharmacoeconomics 1996; 9 (2): 156–67

    Article  PubMed  CAS  Google Scholar 

  42. Le Pen C, Levy E, Bonte J. Cost-effectiveness analysis of captopril treatment after myocardial infarction. Arch Mal Coeur Vaiss 1994; 87 (6): 775–81

    Google Scholar 

  43. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy. J Am Coll Cardiol 1995; 26 (4): 914–9

    Article  PubMed  CAS  Google Scholar 

  44. Michel BC, Al MJ, Remme WJ, et al. Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands [see comments]. Eur Heart J 1996; 17 (5): 731–40

    Article  PubMed  CAS  Google Scholar 

  45. Hummel S, Piercy J, Wright R, et al. An economic analysis of the Survival And Ventricular Enlargment (SAVE) study: application to United Kingdom. Pharmacoeconomics 1997; 12: 183–91

    Article  Google Scholar 

  46. Erhardt L, Ball S, Andersson F, et al. Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy [published erratum appears in Pharmacoeconomics 1997 Dec; 12 (6): 706]. Pharmacoeconomics 1997; 12 (2 Pt 2): 256–66

    Article  PubMed  CAS  Google Scholar 

  47. Martinez C, Ball SG. Cost-effectiveness of ramipril for patients with clinical evidence of heart failure after acute myocardial infarction. Br J Clin Pract 1995; Suppl. 7/8: S26–32

  48. Schadlich PK, Huppertz E, Brecht JG. Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance. Pharmacoeconomics 1998; 14 (6): 653–69

    Article  PubMed  CAS  Google Scholar 

  49. Le Pen C, Liliu H, Keller T, et al. The economics of TRACE: a cost-effectiveness analysis of trandolapril in post-infarction patients with left ventricular dysfunction. Pharmacoeconomics 1998; 14 (1): 49–58

    Article  Google Scholar 

  50. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–6

    Article  PubMed  CAS  Google Scholar 

  51. Mason J, Drummond M, Torrance G. Some guidelines on the use of cost-effectiveness league tables. BMJ 1993; 306: 570–2

    Article  PubMed  CAS  Google Scholar 

  52. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. Circulation 1994; 90 (4): 1765–73

    Article  Google Scholar 

  53. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353 (9146): 9–13

    Google Scholar 

  54. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334 (21): 1349–55

    Article  PubMed  CAS  Google Scholar 

  55. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353 (9169): 2001–7

    Google Scholar 

  56. Dargie H. CAPRICORN: a multinational, randomized, double-blind study on the effects of carvedilol on mortalilty and morbidity in patients with left ventricular dysfunction after myocardial infarction. American College of Cardiology 50th scientific session; 2001 Mar 18–21; Orlando (FL)

  57. Packer M. COPERNICUS: a multicenter, randomized, double-blind placebo-controlled study to determine the effect of carvedilol on mortality in patients with severe chronic heart failure. American College of Cardiology 50th scientific session; 2001 Mar 18–21; Orlando (FL)

  58. Levy P, Lechat P, Leizorovicz A, et al. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drugs Ther 1998; 12 (3): 301–5

    Article  PubMed  CAS  Google Scholar 

  59. Schadlich PK, Paschen B, Brecht JG. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany. Pharmacoeconomics 1998; 13 (1 Pt 2): 147–55

    Article  PubMed  CAS  Google Scholar 

  60. Malek M, Cunningham-Davis J, Malek L, et al. A cost minimisation analysis of cardiac failure treatment in the UK using CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Int J Clin Pract 1999; 53 (1): 19–23

    PubMed  CAS  Google Scholar 

  61. Varney S. A cost-effectiveness analysis of bisoprolol for heart failure. Eur J Heart Fail 2001; 3: 365–71

    Article  PubMed  CAS  Google Scholar 

  62. Levy P, Mérot JL, Lechat P, et al. Bisoprolol dans l’insuffisance cardiaque: efficacité et coûts dans le cadre français selon CIBIS II. Therapie 2001; 56: 421–5

    PubMed  CAS  Google Scholar 

  63. Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS II). CIBIS II Investigators and Health Economic Group. Eur Heart J 2001; 22: 1021–31

  64. Delea TE, Vera-Llonch M, Richner RE, et al. Cost effectiveness of carvedilol for heart failure. Am J Cardiol 1999; 83 (6): 890–6

    Article  Google Scholar 

  65. Fowler M, Vera-Llonch M, Oster G, et al., Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. J Am Coll Cardiol 2001; 37: 1692–9

    Article  PubMed  CAS  Google Scholar 

  66. Eichorn EJ. Experience with beta-blockers in heart failure mortality trials. Clin Cardiol 1999; 22 Suppl. 5: V21-9

    Google Scholar 

  67. Gregory D, Udelson J, Konstam H. Economic impact of beta blockade in heart failure. Am J Med 2001; 110 Suppl. 7A: 74–80

    Article  Google Scholar 

  68. Paul SD, Kuntz KM, Eagle KA, et al. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure [see comments]. Arch Intern Med 1994; 154 (10): 1143–9

    Article  PubMed  CAS  Google Scholar 

  69. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349 (9054): 747–52

    Article  PubMed  CAS  Google Scholar 

  70. Dasbach EJ, Rich MW, Segal R, et al. The cost-effectiveness of losartan versus captopril in patients with symptomatic heart failure. Cardiology 1999; 91 (3): 189–94

    Article  Google Scholar 

  71. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial, the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355 (9215): 1582–7

    Article  PubMed  CAS  Google Scholar 

  72. Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335 (15): 1107–14

    Article  PubMed  CAS  Google Scholar 

  73. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997; 96 (3): 856–63

    Article  PubMed  CAS  Google Scholar 

  74. Lombardi WL, Litwin SE. Angiotensin-converting enzyme inhibitors: congestive heart failure and beyond. Coron Artery Dis 1999; 10 (6): 361–8

    Article  PubMed  CAS  Google Scholar 

  75. Marius-Nunez AL, Heaney L, Fernandez RN, et al. Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J 1996; 132 (4): 805–8

    Article  PubMed  CAS  Google Scholar 

  76. Cuffe MS, Califf RM, Adams KF, et al. Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. Am Heart J 2000; 139 (1 Pt 1): 15–22

    Article  PubMed  CAS  Google Scholar 

  77. Thackray S, Witte K, Clark AL, et al. Clinical trials update: OPTIME-CHF, PRAISE-2, ALL-HAT. Eur J Heart Fail 2000; 2 (2): 209–12

    Article  PubMed  CAS  Google Scholar 

  78. Wood JM, Close P. Renin inhibitors: cardiovascular drugs of the future? Cardiovasc Drugs Ther 1996; 10 (3): 309–12

    PubMed  CAS  Google Scholar 

  79. Klein H, Auricchio A, Reek S, et al. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am J Cardiol 1999; 83 (5B): D91–7

    Article  Google Scholar 

  80. Cannom DS. Other primary prevention trials-what is clinically and economically necessary? J Interv Card Electrophysiol 2000; 4 Suppl. 1: 109–15

    Article  PubMed  Google Scholar 

  81. Leidy NK, Rentz AM, Zyczynski TM. Evaluating health-related quality-of-life outcomes in patients with congestive heart failure: a review of recent randomised controlled trials. Pharmacoeconomics 1999; 15 (1): 19–46

    Article  PubMed  CAS  Google Scholar 

  82. Berry C, McMurray JJ. A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics 1999; 16 (3): 247–71

    Article  PubMed  CAS  Google Scholar 

  83. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol 1997; 80 (8B): H45–52

    Google Scholar 

  84. Lee AJ. The role of financial incentives in shaping clinical practice patterns and practice efficiency. Am J Cardiol 1997; 80 (8B): H28–32

    Article  Google Scholar 

  85. Goldberg RJ, Meyer TE. Advances and stagnations in heart failure [editorial comment]. Arch Intern Med 1997; 157 (1): 17–9

    Article  PubMed  CAS  Google Scholar 

  86. Auerbach AD, Hamel MB, Davis RB, et al. Resource use and survival of patients hospitalized with congestive heart failure: differences in care by specialty of the attending physician. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments [see comments]. Ann Intern Med 2000; 132 (3): 191–200

    PubMed  CAS  Google Scholar 

  87. McMurray JJ. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors? Eur Heart J 1998; 19 Suppl. L: L15–21

    PubMed  Google Scholar 

  88. Krumholz HM, Vaccarino V, Ellerbeck EF, et al. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons > or = 65 years of age. Am J Cardiol 1997; 79 (5): 581–6

    Article  PubMed  CAS  Google Scholar 

  89. Boccuzzi SJ. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Angiotensin-converting enzyme inhibitors in the management of congestive heart failure: a pharmaceutical industry perspective. Am Heart J 1999; 137 (5): S120–2

    Article  Google Scholar 

  90. Monane M, Bohn RL, Gurwitz JH, et al. Noncompliance with congestive heart failure therapy in the elderly [see comments]. Arch Intern Med 1994; 154 (4): 433–7

    Article  PubMed  CAS  Google Scholar 

  91. Andersson F, Cline C, Ryden-Bergsten T, et al. Angiotensin converting enzyme (ACE) inhibitors and heart failure. The consequences of underprescribing. Pharmacoeconomics 1999; 15 (6): 535–50

    Article  Google Scholar 

  92. Bradford D, Chen J, Krumholz M. Under-utilization of beta-blockers after acute myocardial infarction, pharmacoeconomic implications. Pharmacoeconomics 1999; 15 (3): 257–68

    Article  PubMed  CAS  Google Scholar 

  93. McMurray JV, McDonagh TA, Davie AP, et al. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? Eur Heart J 1998; 19 (6): 842–6

    Article  PubMed  CAS  Google Scholar 

  94. Afzal A, Brawner CA, Keteyian SJ. Exercise training in heart failure. Prog Cardiovasc Dis 1998; 41 (3): 175–90

    Article  PubMed  CAS  Google Scholar 

  95. Kornowski R, Zeeli D, Averbuch M, et al. Intensive home-care surveillance prevents hospitalization and improves morbidity rates among elderly patients with severe congestive heart failure. Am Heart J 1995; 129 (4): 762–6

    Article  PubMed  CAS  Google Scholar 

  96. Paul S. Impact of a nurse-managed heart failure clinic: a pilot study. Am J Crit Care 2000; 9 (2): 140–6

    PubMed  CAS  Google Scholar 

  97. Stewart S. An economic analysis of specialist nurse management of heart failure: can we afford not to implement it? [abstract]. Eur Heart J 2001; 22: 626

    Google Scholar 

  98. Bouhour JB. Education of patients with heart failure. Arch Mal Coeur Vaiss 1998; 91 (11): 1407–10

    Google Scholar 

  99. Rich MW, Vinson JM, Sperry JC, et al. Prevention of readmission in elderly patients with congestive heart failure: results of a prospective, randomized pilot study. J Gen Intern Med 1993; 8 (11): 585–90

    Article  PubMed  CAS  Google Scholar 

  100. Fonarow GC, Stevenson LW, Walden JA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 1997; 30 (3): 725–32

    Article  PubMed  CAS  Google Scholar 

  101. Cline CM, Israelsson BY, Willenheimer RB, et al. Cost effective management programme for heart failure reduces hospitalisation [see comments]. Heart 1998; 80 (5): 442–6

    PubMed  CAS  Google Scholar 

  102. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190–5

    Article  PubMed  CAS  Google Scholar 

  103. Whellan DJ, Gaulden L, Gattis WA, et al. The benefit of implementing a heart failure disease management program. Arch Intern Med 2001; 161: 2223–8

    Article  PubMed  CAS  Google Scholar 

  104. Schulman KA, Mark DB, Califf RM. Outcomes and costs within a disease management program for advanced congestive heart failure. Am Heart J 1998; 135 (6 Pt 2 Su): S285–92

    Article  PubMed  CAS  Google Scholar 

  105. McAlister FA, Lawson FM, Teo KK, et al. A systematic review of randomized trials of disease management programs in heart failure. Am J Med 2001; 110 (5): 378–84

    Article  PubMed  CAS  Google Scholar 

  106. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, et al. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999; 353 (9164): 1547–57

    Article  PubMed  CAS  Google Scholar 

  107. Cleland JG. Improving patient outcomes in heart failure: evidence and barriers. Heart 2000; 84 Suppl. 1: i8–10, i50

    Article  PubMed  Google Scholar 

  108. Coats AJ. Beta-blockers: again, a lesson to us all, especially the research funding community [editorial]. Int J Cardiol 2000; 73 (2): 103–4

    Article  PubMed  CAS  Google Scholar 

  109. Schulman KA, Glick H, Buxton M, et al. The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial. Control Clin Trials 1996; 17 (4): 304–15

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This publication had no support from any institution or laboratory.

Author information

Authors and Affiliations

  1. LEGOS (Laboratory of Health Organization Economics and Management), Paris Dauphine University, Place du Maréchal de Lattre de Tassigny, Paris, 75116, France

    Emile Levy & Pierre Levy

Authors
  1. Emile Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emile Levy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levy, E., Levy, P. Pharmacoeconomic Considerations in Assessing and Selecting Congestive Heart Failure Therapies. Pharmacoeconomics 20, 963–977 (2002). https://doi.org/10.2165/00019053-200220140-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200220140-00002

Keywords

Search

Navigation